Celcuity Ships Its First Drug Into the Corner of Breast Cancer No PI3K Label Covered
Celcuity's REVTORPYK became commercially available September 30, claiming the PIK3CA wild-type corner of second-line HR-positive breast cancer no approved PI3K or AKT label covers. The launch must now overcome an immature survival read, heavy stomatitis, and a weekly IV schedule.
On September 30, 2026, Celcuity announced that REVTORPYK (gedatolisib) is now commercially available in the United States, the first drug the Minneapolis biotech has ever brought to market. The label is narrow by design: adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors carry no PIK3CA mutation, after progression on endocrine therapy in the metastatic setting. That narrowness is the point. Every other approved inhibitor of the PI3K/AKT/mTOR pathway, the so-called PAM pathway, requires or effectively presumes an alteration in it.
The market Celcuity is entering has three incumbents, and none of them is built for the wild-type patient. AstraZeneca's capivasertib (Truqap) won approval in November 2023 only for tumors with a PIK3CA, AKT1, or PTEN alteration detected by an FDA-approved test. Its pivotal trial, CAPItello-291, reported a hazard ratio of 0.79 in the 313 patients without such an alteration, an exploratory analysis with a confidence interval touching 1.0, so the overall benefit rests on the mutated subgroup. Alpelisib (Piqray) and inavolisib (Itovebi) are alpha-selective, mutation-dependent agents. None of the approved pathway drugs claims the patient whose tumor progressed on a CDK4/6 inhibitor with an intact PIK3CA gene. Gedatolisib does, inhibiting all four class I PI3K isoforms plus mTORC1 and mTORC2.
What the wild-type cohort means clinically
These are patients who have already failed the modern standard: an aromatase inhibitor, then a CDK4/6 inhibitor, typically with fulvestrant. Their options narrow to further endocrine sequencing or chemotherapy, none of it aimed at the pathway driving their disease. The VIKTORIA-1 wild-type cohort, published in the Journal of Clinical Oncology in March, is the first Phase 3 study to show a significant progression-free survival gain from PI3K/AKT/mTOR inhibition in this population, according to lead author Sara Hurvitz of the Fred Hutchinson Cancer Center.
The trial enrolled 392 patients and randomized them to a triplet of gedatolisib, fulvestrant, and palbociclib, a doublet without palbociclib, or fulvestrant alone. Median progression-free survival was 9.3 months for the triplet and 7.4 months for the doublet, against 2.0 months for fulvestrant. Response rates were 32 percent and 28 percent versus 1 percent, and responses lasted a median of 17.5 and 12.0 months. The FDA reviewed the application under its Real-Time Oncology Review program and approved the drug on July 14, 2026.
The caveats the label carries
Two should temper the enthusiasm. VIKTORIA-1 was open-label, so the 2.0-month comparator arm, fulvestrant alone after a CDK4/6 failure, is a control patients and investigators could see coming. And overall survival data are immature: only 25 percent of patients in the overall population had died at the time of the PFS analysis. The endpoints cover progression, not survival, and the survival picture is not yet drawn.
The price of pan-blockade
The other trade is tolerability and logistics. Stomatitis hit 72 percent of triplet patients in the label, Grade 3 in 22 percent, and 58 percent of doublet patients, which is why the label directs prophylactic use of a steroid-containing, alcohol-free mouthwash. Rash appeared in 30 to 40 percent and elevated fasting glucose in 46 to 57 percent. From the JCO cohort, Grade 3 treatment-related events in the triplet arm were led by neutropenia at 52.3 percent and stomatitis at 19.2 percent, though treatment discontinuation stayed low at 2.3 percent. Pan-blockade also arrives as a weekly intravenous infusion, 180 mg over 30 minutes on days 1, 8, and 15 of each cycle, a clinic visit three weeks out of four. Competing oral agents do not ask that of patients.
A first launch on a levered balance sheet
Celcuity is funding this launch without a commercial track record. Its Q2 filing with the SEC showed a net loss of $78.9 million, SG&A that jumped from $7.6 million to $35.0 million as it hired a commercial team, and $754.0 million in cash expected to fund operations into 2029. That figure already includes a June 2026 issuance of $575.0 million in 0.250 percent convertible notes, $137.0 million of which prepaid existing debt. Underlying the launch is a licensing arrangement with Pfizer: up to $335.0 million in aggregate milestone payments and low to mid-teens royalties on sales, per the company's filing.
The mitigations are already visible. NCCN added the regimen as a preferred Category 1 second-line option. An sNDA for the PIK3CA-mutant setting went in during August, backed by data showing the triplet doubling PFS against alpelisib with a fraction of its discontinuation rate, which would extend the label to the PIK3CA-mutant setting. And a subcutaneous formulation is in development to replace the weekly infusion, the single biggest friction in the regimen.
What the launch must prove
REVTORPYK now owns a defensible clinical position: the only approved PAM inhibitor for PIK3CA wild-type disease. Whether that position converts to revenue depends on whether oncologists and patients accept a weekly infusion and a managed stomatitis profile for about seven months of added progression-free survival, and whether a first-time commercial organization can execute against $754 million that has to last until 2029. The company has bought itself the window. Now it has to sell into it.